Rigel Pharmaceuticals
RIGL
138 hedge funds and large institutions have $150M invested in Rigel Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 18 closing their positions.
251% more call options, than puts
Call options by funds: $579K | Put options by funds: $165K
26% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 35
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
2% more funds holding
Funds holding: 135 → 138 (+3)
0.69% less ownership
Funds ownership: 8.09% → 7.4% (-0.69%)
4% less capital invested
Capital invested by funds: $157M → $150M (-$6.88M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.89M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$4.71M |
| 3 |
AC
Armistice Capital
New York
|
+$4.67M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4M |
| 5 |
Two Sigma Advisers
New York
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$27.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.7M |
| 3 |
Citigroup
New York
|
-$2.08M |
| 4 |
Morgan Stanley
New York
|
-$1.74M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.61M |
RIGL Hedge Fund Activity: Q3 2022 in Review
138 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2022, worth a combined $150M — down 4.4% from $157M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RIGL positions and 18 closed out — a net gain of 3 holders — while 44 added to existing stakes and 35 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.89M. The largest seller was State Street, cutting an estimated $27.1M.
- 138 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2022, up from 135 in Q2 2022.
- Funds reported $150M of Rigel Pharmaceuticals stock for Q3 2022, down 4.4% quarter-over-quarter.
- 21 funds opened new Rigel Pharmaceuticals positions in Q3 2022 and 18 closed out, a net change of +3 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2022 was Millennium Management, an estimated $8.89M added.
- The largest Rigel Pharmaceuticals seller in Q3 2022 was State Street, an estimated $27.1M sold.
Based on aggregated 13F filings for Q3 2022.